Content
01/13/2025
Durham, NC USA
Tune Therapeutics
completed $175 million Series B Round funding. Investors include
Hevolution Foundation, New Enterprise Associates, Regeneron Ventures, Yosemite.
About
Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine- expanding their range of application to common and chronic diseases.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
